Precise Dx Secures $20.7 Million Series B to AdvanceAI-Powered Cancer Risk Assessments
Longview News-Journal Precise Breast™ is an early-stage invasive breast cancerriskassessment, independent of HER2, and hormone receptor status. TheAI-powered test …
Read the original at news-journal.com ↗
- Topics
- Healthcare
- Tags
- AI Use Case
- Tracked via
- Google Alert “AI Risks”